15 completed, 12 active not recruiting, 6 terminated, 3 recruiting. 22 Phase 2, 15 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 220 | 2025-09-10 | 2026-11-03 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Drug Screening Using IMD in Bladder Cancer Implantable Micro-Device, Methotrexate, Carboplatin - Muscle Invasive Bladder Urothelial Carcinoma | Early Phase 1 | Enrolling by invitation | Brigham and Women's Hospital | 18 | 2024-06-14 | 2026-05-18 |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer TAR-210, Gemcitabine, MMC - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 641 | 2024-04-18 | 2026-11-03 |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2024-01-04 | 2026-10-15 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-11-12 |
| Erdafitinib in Metastatic Steroid-cell Ovarian Cancer Erdafitinib - Ovarian Cancer, Steroid Cell Tumor, Malignant | Not applicable | Completed | University Health Network, Toronto | 1 | 2022-05-30 | 2024-03-25 |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Erdafitinib Intravesical Delivery System - Non-Muscle Invasive Bladder Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 235 | 2022-04-11 | 2026-11-03 |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Erdafitinib - Bladder Cancer, Recurrent Bladder Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-02-17 | 2026-09-02 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib Balversa - Bladder Cancer, Urothelial Carcinoma | Terminated | xCures | 2 | 2021-11-21 | 2022-12-22 | |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Erdafitinib - Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2021-07-15 | 2026-02-06 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Abiraterone Acetate, Enzalutamide, Erdafitinib - Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma | Phase 2 | Terminated | University of Washington | 3 | 2020-04-27 | 2023-09-28 |
| A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants Erdafitinib, Carbamazepine - Healthy | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 15 | 2020-03-31 | 2023-06-29 |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C) - Urinary Bladder Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 107 | 2020-02-28 | 2026-02-24 |
| A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations Erdafitinib - Advanced Solid Tumor | Phase 2 | Completed | Janssen Research & Development, LLC | 316 | 2019-11-20 | 2026-09-17 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| FGFR Inhibitor in FGFR Dysregulated Cancer ERDAFITINIB - Lung Cancer, NSCLC | Phase 2 | Terminated | Lung Cancer Group Cologne | 22 | 2019-03-25 | 2023-06-09 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib Erdafitinib - Hepatic Impairment | Phase 1 | Terminated | Janssen Research & Development, LLC | 26 | 2018-12-06 | 2025-02-03 |
Showing 20 of 40. Sign in to see all of them.
Urinary Bladder Neoplasms (7) · Non-Muscle Invasive Bladder Neoplasms (5) · Carcinoma, Transitional Cell (4) · Glioma (4) · Multiple Myeloma (4) · Neoplasms (3) · Prostatic Neoplasms (3) · Acrocephalosyndactylia (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Esophageal Neoplasms (2) · Hepatoblastoma (2)
Janssen Research & Development, LLC (16) · National Cancer Institute (NCI) (8) · Janssen Pharmaceutical K.K. (2) · University Health Network, Toronto (2) · Brigham and Women's Hospital (1) · Janssen Scientific Affairs, LLC (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Lung Cancer Group Cologne (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Multiple Myeloma Research Consortium (1) · Peking University Shenzhen Hospital (1) · The Netherlands Cancer Institute (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (24) · Belgium (11) · South Korea (10) · Germany (9) · Japan (8) · Spain (8) · China (7) · France (7) · Taiwan (7) · United Kingdom (7) · Brazil (6) · Canada (6) · Italy (6) · Argentina (5) · Israel (5)
Alain C Mita (2) · Alice Lee (1) · Amit Oza, M.D. (1) · Brent Rexer, MD, PhD (1) · Daniel J. George, MD (1) · Di Maria Jiang (1) · Donald W Parsons (1) · E.E. Voest, prof. (1) · Eugene Pietzak, MD (1) · Hearn J Cho, M.D., Ph.D. (1)
PMID 26586415, PMID 31340094, PMID 31401903, PMID 31673875, PMID 32463741, PMID 33048619, PMID 33591402, PMID 34125951, PMID 34977972, PMID 35030333, PMID 35086719, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35598186, PMID 36351402, PMID 36639200, PMID 36870947, PMID 37053535, PMID 37322121, PMID 37424386, PMID 37541273, PMID 37870920, PMID 37934000, PMID 38591867, PMID 38630551, PMID 39138436, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39971605, PMID 40627530, PMID 40675687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 41538748, PMID 41986720, PMID 42456086, PMID 42686334
2023 (6), 2014 (3), 2017 (3), 2019 (3), U10CA180820 (3), UM1CA186644 (3), 2018 (2), U10CA180886 (2), U24CA196172 (1), UM1CA081457 (1)